Stock 0GY1 SWEDISH ORPHAN BIOVITRUM
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Press Releases SWEDISH ORPHAN BIOVITRUM London S.E.

Equities

0GY1

End-of-day quote London S.E.
Other stock markets
- SEK - Intraday chart for SWEDISH ORPHAN BIOVITRUM
06-19 Sobi Wins EU Approval for Hemophilia A Drug Altuvoct MT
06-19 European Commission Grants Sobi® Marketing Authorisation for Altuvoct? for Treatment of Haemophilia A CI

Press Releases

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Swedish Orphan Biovitrum : European Commission grants Sobi® Marketing Authorisation for ALTUVOCT™ for treatment of haemophilia A
PU
Swedish Orphan Biovitrum : Sobi to present new haemophilia data at ISTH 2024
PU
Swedish Orphan Biovitrum : Sobi to present new data across its haematology portfolio at the 2024 EHA congress
PU
Sobi to present new myelofibrosis data at the ASCO 2024 Annual Meeting
GL
Sobi Receives US FDA Fast Track Designation for Emapalumab-lzsg being investigated in Macrophage Activation Syndrome
GL
Bulletin from Sobi's Annual General Meeting (AGM)
AQ
Sobi has completed SEK 3 billion senior bond issue
AQ
Aspaveli® (pegcetacoplan) approved in Europe for use among treatment naïve adult patients with PNH
AQ
Sobi® receives positive CHMP opinion recommending approval of efanesoctocog alfa for once-weekly treatment of haemophilia A
AQ
Sobi establishes MTN programme with a framework amount of SEK 10 billion, publishes a base prospectus
AQ
Swedish Orphan Biovitrum : 25 april - Q1 2024 rapport
PU
Swedish Orphan Biovitrum : 25 April - Q1 2024 report
PU
Sobi Q1 2024 report: Strong sales reflecting the strength of the portfolio
AQ
Invitation: Sobi's Q1 2024 report
PU
Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ)
AQ
Swedish Orphan Biovitrum : Sobi publishes Annual and sustainability report for 2023
PU
Sobi publishes Annual and sustainability report for 2023
AQ
Swedish Orphan Biovitrum : Sobi announces positive results from phase 3 study of Doptelet® for treatment of children and adolescents with ITP
PU
Sobi publishes Q4 2023 report: Strong revenue performance and growth into 2024
AQ
Sobi to present new data at EAHAD 2024
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SOBI Stock
  4. 0GY1 Stock
  5. News SWEDISH ORPHAN BIOVITRUM
  6. Press Releases